Insider Buying: MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Acquires $16,301.63 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero bought 11,899 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was acquired at an average price of $1.37 per share, for a total transaction of $16,301.63. Following the purchase, the director directly owned 600,117 shares in the company, valued at approximately $822,160.29. The trade was a 2.02% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Ramiro Guerrero also recently made the following trade(s):

• On Monday, August 24th, Ramiro Guerrero bought 1,794 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $1.33 per share, with a total value of $2,386.02.

MAIA Biotechnology Trading Down 1.4%

Shares of MAIA opened at $1.39 on Thursday. The stock has a 50 day moving average of $1.38 and a 200 day moving average of $1.45. The company has a market capitalization of $84.55 million, a price-to-earnings ratio of -2.24 and a beta of 0.24. MAIA Biotechnology, Inc. has a 12 month low of $0.87 and a 12 month high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, equities research analysts predict that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current year.

Hedge Funds Weigh In On MAIA Biotechnology

Several institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new stake in MAIA Biotechnology in the second quarter worth about $29,000. PVG Asset Management Corp bought a new position in shares of MAIA Biotechnology during the 1st quarter valued at approximately $46,000. Susquehanna International Group LLP purchased a new stake in shares of MAIA Biotechnology during the 2nd quarter worth approximately $51,000. Jane Street Group LLC purchased a new stake in shares of MAIA Biotechnology during the 2nd quarter worth approximately $52,000. Finally, Corsair Capital Management L.P. bought a new stake in shares of MAIA Biotechnology in the 1st quarter worth approximately $140,000. Institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.